Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GRPR PET/CT · 1 trial · 1 indication
Proportion of participants with at least one GRPR-positive lesion on \[⁶⁸Ga\]-LY4257529 PET/CT. Detection rate will be calculated as the number of participants with at least one GRPR-positive lesion divided by the total number of participants in the relevant cancer cohort.
| Arm | Type | Description |
|---|---|---|
| [⁶⁸Ga]-GRPR PET/CT | EXPERIMENTAL | Participants with breast cancer or other selected GRPR-expressing malignancies will receive a single intravenous administration of approximately 170 MBq ±20% of \[⁶⁸Ga\]-LY4257529, followed by PET/CT imaging approximately 50-70 minutes after injection. All participants undergo the same imaging intervention. |
| Name | Type | Description |
|---|---|---|
| GRPR PET/CT | DIAGNOSTIC_TEST | \[⁶⁸Ga\]-LY4257529 is an investigational gastrin-releasing peptide receptor (GRPR)-targeted PET radiopharmaceutical. Participants will receive approximately 170 MBq ±20% (4.6 mCi ±20%) intravenously. PET/CT imaging will begin approximately 50-70 minutes after administration to evaluate GRPR-targeted tumor uptake and distribution. |
Inclusion Criteria: Age 18 years or older Able to understand and provide written informed consent Diagnosis of a breast cancer or other tumor known or suspected to express GRPR, including: ER-positive/HER2-negative breast cancer Invasive lobular breast cancer Head and neck squamous cell carcinoma...